Clinical trial · Observational
Health Related Quality of Life and Multidimensional Evaluations of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist Therapy
Health Related Quality of Life and Multidimensional Evaluations of a Cohort of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist Therapy
NCT03516110CI-TRIAL-00101540PRISMEcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of the study is to compare the evolution over 6 months of Health-Related Quality of Life (HRQOL) among different age groups in subjects with prostate cancer treated with GnRH agonist therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Data collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Prostate cancer subjects 60-<70 years
- interventionNames
- Other: Data collection
- label
- Prostate cancer subjects 70-<75 years
- interventionNames
- Other: Data collection
- label
- Prostate cancer subjects ≥ 75 years
- interventionNames
- Other: Data collection
Primary outcomes (1)
- measure
- Quality of Life (QOL) as evaluated by Quality of Life Questionnaire-Elderly 14 items (QLQ-ELD-14)
- timeFrame
- Change from baseline at 6 months
- description
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Subject presenting with histologically confirmed prostate cancer * Subject of 60 years and older * Subject eligible to start GnRH agonist therapy, either as monotherapy or adjuvant therapy, and for whom one of these treatments was selected voluntarily by the investigator, prior to the start of the study * Subject giving his written consent to participate in the study * Subject able to complete questionnaires Exclusion Criteria: * Subject simultaneously participating in a clinical trial * Subject who previously received a hormonal therapy during the last 6 months before inclusion
References
Publications (0)
Data not yet available
No reference posted for this study.